Phase Genomics
American genomic sequencing company
From Wikipedia, the free encyclopedia
Phase Genomics is an American biotechnology company based in Seattle, Washington. The company develops proximity ligation kits and Hi-C sequencing technology used to analyze chromosomes. Phase Genomics sells proximity ligation kits, scientific services, and computational analyses.
| Type | Startup company |
|---|---|
| Industry | Biotechnology |
| Founded | 2015 |
| Founders | Ivan Liachko, Shawn Sullivan |
| Headquarters | Seattle, Washington, US |
| Key people | Ivan Liachko (CEO, president), Shawn Sullivan (CTO) |
| Website | phasegenomics |
History
The company was founded by Ivan Liachko and Shawn Sullivan in 2015. It was originally housed in the CoMotion biotech incubator at University of Washington before relocating to a separate facility. It develops proximity ligation kits and Hi-C sequencing technology used to analyze chromosomes. The company sells proximity ligation kits, scientific services, and computational analyses.[1]
Research
Phase Genomics developed a library preparation kit for the Hi-C sequencing method previously developed by researchers Job Dekker and Eric Lander. The kits are used to study the architecture of genomes.[2] In 2018, Phase Genomics received a $1.5 million SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to research antimicrobial resistance using Hi-C technology. In January 2020, it was awarded an additional $1.5 million from NIAID for phase 2 SBIR funding.[3] In 2019, Phase Genomics received $200,000 from the Bill & Melinda Gates Foundation to improve computational methods of extracting genomic data in microbiome samples.[3][4] Later in 2019, the company was awarded $325,000 from the U.S. Department of Energy to research algae biofuels using proximity litigation technology for metagenome assembly.[4] In 2020, Phase Genomics received 2 grants totaling $3.9 million from the National Human Genome Research Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The 3-year grants fund research on chromosomal abnormalities causing cancer, infertility, and reproductive issues.[1]
In June 2021, the company released a platform for discovering new viruses in microbiome samples.[5][6]